PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis

Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL cells in treated patients overexpress multiple antiapoptotic proteins and display resistance to proapoptotic agents. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayappa, Kallesh D., Tran, Brian, Gordon, Vicki L., Morris, Christopher, Saha, Shekhar, Farrington, Caroline C., O’Connor, Caitlin M., Zawacki, Kaitlin P., Isaac, Krista M., Kester, Mark, Bender, Timothy P., Williams, Michael E., Portell, Craig A., Weber, Michael J., Narla, Goutham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313372/
https://www.ncbi.nlm.nih.gov/pubmed/37166997
http://dx.doi.org/10.1172/JCI155938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313372/
https://www.ncbi.nlm.nih.gov/pubmed/37166997
http://dx.doi.org/10.1172/JCI155938

Ejemplares similares